{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:56:45Z","timestamp":1787317005328,"version":"build-2736575974"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Brentuximab vedotin (BV) is a monoclonal antibody that targets CD30 antigen. It is indicated for the treatment of CD30\u2009+\u2009lymphomas and classical Hodgkin lymphoma (HL), including advanced (stage III-IV) untreated disease, relapsed\/refractory disease, and consolidation after autologous hematopoietic stem cell transplantation. In clinical trials the incidence of a hypersensitivity reaction is 1.2%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases report<\/jats:title>\n                    <jats:p>\n                      We present 3 cases of patients with refractory HL and anaphylaxis to the administration of BV (\n                      <jats:xref ref-type=\"table\">Table\u00a01<\/jats:xref>\n                      ). Symptoms are analyzed using a grading system described by Brown (2004) and a desensitization protocol was performed with a total dose of 100\u2005mg of BV in 4 solution bags with an initial concentration of 1:1000 of total dose for cases of severe anaphylaxis, and desensitization of 3 solution bags with baseline concentration of 1: 100 for cases of moderate anaphylaxis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Intradermal skin tests were positive. Before desensitization, premedication with methylprednisolone and chlorphenamine was administered, as well as fluid therapy with 0.9% physiological solution at 100 cc\/hour at induction stage, 250 cc\/hour at maintenance stage, and increased to 500 cc\/hour in case of hypersensitivity reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Drug desensitization in 12 or 16 steps allows tolerable administration of brentuximab vedotin after moderate to severe anaphylaxis. The favorable response to treatment of these patients may indicate that desensitization is a viable strategy for patients with relapsed or refractory HL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221074965","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T07:46:23Z","timestamp":1642751183000},"page":"1264-1268","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-6934","authenticated-orcid":false,"given":"Rosalaura V","family":"Villarreal-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-0042","authenticated-orcid":false,"given":"Sandra N","family":"Gonz\u00e1lez-D\u00edaz","sequence":"additional","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J","family":"Santos-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla R","family":"Colunga-Pedraza","sequence":"additional","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Varela-Constantino","sequence":"additional","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[{"name":"University Hospital \u201cDr Jose Eleuterio Gonzalez\u201d"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1","article-title":"Novel targeted therapies of T cell lymphomas","volume":"13","author":"I\u017cykowska K","unstructured":"I\u017cykowska K, Rassek K, Korsak D, et al. Novel targeted therapies of T cell lymphomas. J Hematol Oncol 2020 Dec; 13: 1\u201338.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.001"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12570"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8556-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.07.003"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.01.011"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2838"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0052"},{"key":"e_1_3_3_11_2","first-page":"626","article-title":"Brentuximab vedotin infusion reaction management: a case study","volume":"8","author":"Comer H","unstructured":"Comer H, Cardwell K. Brentuximab vedotin infusion reaction management: a case study. J Adv Pract Oncol 2017 Sep; 8: 626.","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220942292"},{"key":"e_1_3_3_13_2","first-page":"749","article-title":"Successful desensitization to brentuximab vedotin after hypersensitivity reaction","volume":"13","author":"Story SK","unstructured":"Story SK, Petrov AA, Geskin LJ. Successful desensitization to brentuximab vedotin after hypersensitivity reaction. J Drugs Dermatol 2014 Jun 1; 13: 749\u2013751.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_14_2","article-title":"Desensitization of brentuximab vedotin in a patient with hodgkin lymphoma","volume":"10","author":"Khalid S","unstructured":"Khalid S, Khalid A, Clark BA, et al. Desensitization of brentuximab vedotin in a patient with hodgkin lymphoma. Cureus 2018 Jul 13; 10: e2981.","journal-title":"Cureus"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.11.003"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Fizesan M Boin C Aujoulat O et al. Successful rapid desensitization to the antibody\u2013drug conjugate brentuximab vedotin in a patient with refractory hodgkin lymphoma. J Oncol Pharm Practice 2015: 1\u20135.","DOI":"10.1177\/1078155214567164"},{"key":"e_1_3_3_17_2","first-page":"1","article-title":"Rapid desensitization for brentuximab vedotin (adceteris\u00ae) allergy: a case report","volume":"16","author":"Di Girolamo A","unstructured":"Di Girolamo A, Albanesi M, Sinisi A, et al. Rapid desensitization for brentuximab vedotin (adceteris\u00ae) allergy: a case report. Clin Mol Allergy 2018 Dec; 16: 1\u20134.","journal-title":"Clin Mol Allergy"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221074965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:01Z","timestamp":1779194221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221074965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552221074965"],"URL":"https:\/\/doi.org\/10.1177\/10781552221074965","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}